Quadracel Vaccine Composition
Quadracel is a combination vaccine that contains diphtheria and tetanus toxoids, acellular pertussis antigens, and inactivated poliovirus types 1,2, and 3 (DTaP-IPV). 1
Specific Vaccine Components
Pertussis Antigens
- Inactivated pertussis toxin (PT) 1
- Filamentous hemagglutinin (FHA) 1
- Pertactin 1
- Inactivated poliovirus types 1,2, and 3 1
Toxoids
Licensed Indications
Quadracel is FDA-licensed specifically as the fifth dose of the DTaP vaccine series and the fourth or fifth dose of the IPV series in children aged 4 through 6 years. 1
Key Licensing Requirements
- Children must have previously received 4 doses of Pentacel (DTaP-IPV/Hib) and/or Daptacel (DTaP) vaccine to be eligible for Quadracel 1, 2
- The vaccine is approved for use only in children aged 4 through 6 years 1
Immunogenicity Profile
The immunogenicity of all antigens in Quadracel was demonstrated to be noninferior to separately administered DTaP (Daptacel) and IPV (IPOL) vaccines. 1
Clinical Performance
- Quadracel can be administered with or without concomitant MMR and varicella vaccines without affecting immune responses 1
- The vaccine provides comparable safety and immunogenicity to separately administered component vaccines 1, 3
Important Clinical Caveats
Quadracel does NOT contain Hepatitis B or Haemophilus influenzae type b (Hib) antigens, unlike some other combination vaccines such as Pediarix (which contains DTaP-IPV-HepB) or Pentacel (which contains DTaP-IPV/Hib). 1
The vaccine is manufactured by Sanofi Pasteur and is specifically designed to reduce the total number of injections required at the 4-6 year visit by combining the final DTaP and IPV doses into a single injection. 1, 3, 2